Bulls HW, et al. - Researchers examined 90 gynecologic cancer patients treated with cytoxic chemotherapy, to assess longitudinal change in patient-reported chemotherapy-induced peripheral neuropathy (CIPN) symptoms from the start of chemotherapy to one year post-chemotherapy as well as to analyze treatment modifications in older (≥65 years) and younger patients (<65 years). These patients, via the EORTC-CIPN20, mentioned their CIPN symptoms three times during active treatment and at 6 and 12 months post-treatment. Also, medical record of these patients were analyzed. During the active treatment phase, similar increases in CIPN were reported by older and younger patients. However, a higher risk for chronic CIPN was observed among older adults, regarding which these subjects may need additional education and treatment. Findings revealed no age differences in the presence of provider-recorded sensory neuropathy and pain; neuropathy-related treatment delays, changes in chemotherapy dose, regimen, or discontinuations; or falls.